|
|
|
|
||
Re: What is still missing is an equity offeringI agree that investors should always take stock (pardon the pun) of the unforeseen. In fact, ACAD investors have had a taste of it in recent years. Who could've guessed at the end of 2014, for instance, that Dr. Uli Hacksell was going to be fired the following March, that the NDA was going to be delayed several more months, and that Roger Mills, who for years co-authored scholarly papers on pimavanserin, would be out three months after the NDA was filed? Who could possibly have guessed that the share price would reach an all-time high (51.99) in July 2015, a full 9 months before FDA approval of Nuplazid? If someone in 2014 said the stock would trade at 34 and change at the end of March 2017, would any of us have believed him? So your admonition on that score holds up well. It's less convincing when the focus is narrowed to particulars. Again, my comments in red: "Safety - 10 months is a short time when you expect to be selling this for a decade or more." {We've known about pimavanserin for 15 years. One patient has been on the drug for over 10 years and has tolerated it well. Hundreds of patients have been on the drug for over two years without reporting an SAE. Pimavanserin has been tested at doses 4 times that recommended/prescribed, and the commonest side effect was merely nausea. The drug is nowhere near as pharmacologically active as its peers quetiapine and clozapine, and they're still on the market.} Cures - breakthroughs occur all the time....who knows? {I disagree. Breakthroughs do not "occur all the time." They happen infrequently and are the product of decades of research. Me-too drugs, bio-similars far outnumber breakthroughs.} Competition - from whom? From someone you have no knowledge of, someone off your radar screen. {In this day and age of instantaneous information, online forums sharing ideas and tips, investors large and small scouring news sources foreign and domestic, it's highly unlikely a company can emerge ex nihilo as a competitor. And in the rare cases when that happens, it tends to be a company unearthing pre-clinical findings of something.} |
return to message board, top of board |